Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Chromatics Color Sciences International. Inc; CCSI -- Ignore unavailable to you. Want to Upgrade?

To: JanyBlueEyes who wrote (4948)	3/10/1999 9:21:00 PM
From: Cacaito	Read Replies (2) \| Respond to of 5736

Janybird, at time Robin called, Sprx was on the mute period with FDA, to try to disseminate information is against FDA rules. Try calling any company in same conditions, answer will be the same: no comments. So far, cero scientific evidence to say BiliCheck does not work in patients on phototherapy. The technology is the same, infrared reflectance spectral analysis. Only if light can not travel back and forth across skin tissue the devices (both the Colormate and the BiliCheck) will be affected. Yes, the Market has spoken today: Sprx up 10% in 5 times volume. CCSI down 8% in 1.5 volume. Plus the recent plunge. This is a good pair trade: Short CCSI, Long SPRX. The prices will diverge opposite. If when anybody brings information confirming that the BiliCheck is unable to work "due to skin changes during phototherapy" I will gladly go the other way.